RenovoRx presents pharmacokinetic data at ASCO meeting

RenovoRx Inc. (NASDAQ: RNXT) announced that pharmacokinetic data from a sub-study of its Phase III TIGeR-PaC clinical trial was published in connection with the 2026 American Society of Clinical Oncology Annual Meeting held May 29 through June 2 in Chicago.

The sub-study examined the company's TAMP platform for targeted intra-arterial delivery of gemcitabine via its RenovoCath device in locally advanced pancreatic cancer patients. The analysis involved 16 patients across six trial sites and compared intra-arterial gemcitabine administration with intravenous delivery.

Results showed that intra-arterial gemcitabine administration correlated with increased metabolite levels and reduced CA 19-9, a biomarker used to assess chemotherapy response. The data indicated that this delivery method may decrease systemic gemcitabine levels through limited systemic exposure and rapid conversion to an inactive metabolite.

"This study suggests that enhancing local drug potency while reducing systemic exposure with IAG may increase efficacy while minimizing toxicity, addressing a key limitation of many therapies," said co-author Dr. Reza Nazemzadeh of Atrium Health Levine Cancer Institute.

RenovoRx reported $563,000 in RenovoCath sales for the first quarter of 2026 and approximately $1.1 million in sales for 2025. The company expects full enrollment in the TIGeR-PaC trial in June 2026 with final data readout anticipated in mid to late 2027.

The RenovoCath device received FDA clearance for vessel occlusion applications including chemotherapeutic drug infusion. The intra-arterial gemcitabine combination received Orphan Drug Designation for pancreatic and bile duct cancers.

You May Also Be Interested In

• Cantor Fitzgerald Starts Tempus AI Inc (TEM) at Overweight
• aTyr Pharma expects FDA response on Phase 3 sarcoidosis trial by mid-Sept
• Ultragenyx publishes 96-week phase 3 data for GSDIa gene therapy